Puylaert Kevin sold $1K of SOPH
Puylaert Kevin (Chief Sales Officer) sold 216 shares of SOPHiA GENETICS SA (SOPH) at an average of $5.03 ($5.03–$5.09) across 3 trades on 2026-07-06.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on insider activity but does not include new operational, financial, or regulatory information that would reset valuation expectations.
Market read
Traders may note the insider sale, but the small size and lack of 10b5-1 plan context reduce its standalone trading significance.
What to watch
Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the disclosed value (~$1.1k) is too small to imply a material change in company outlook.
Background
This is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA (SOPH).
Ticker impact
SEC Form 4 shows SOPHiA GENETICS insider Puylaert Kevin sold 216 shares at ~$5.03 on 2026-07-06, totaling ~$1,087.
Minimal near-term price impact expected; any effect is likely short-lived and not a standalone catalyst.
The filing is a small, non-10b5-1 sale by a Chief Sales Officer with modest dollar value and no accompanying guidance, deal, or regulatory event.
Market effects
No clear sector read-through from a small, routine insider sale.
None indicated.
None indicated.
Counterpoint
The absence of a 10b5-1 plan could be interpreted as discretionary selling, which some traders may view as mildly bearish.
Key entities
- issuerSOPHiA GENETICS SA
Company whose insider sale is disclosed on Form 4.
- insiderPuylaert Kevin
Chief Sales Officer who sold 216 shares in open-market transactions.
